Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
Open Access
- 15 July 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (14), 5643-5647
- https://doi.org/10.1158/0008-5472.can-09-0487
Abstract
Cancer patients receiving epidermal growth factor receptor (EGFR) antibody therapy often experience an acneiform rash of uncertain etiology in skin regions rich in pilosebaceous units. Currently, this condition is treated symptomatically with very limited, often anecdotal success. Here, we show that a monoclonal antibody targeting murine EGFR, ME1, caused a neutrophil-rich hair follicle inflammation in mice, similar to that reported in patients. This effect was preceded by the appearance of lipid-filled hair follicle distensions adjacent to enlarged sebaceous glands. The cytokine tumor necrosis factor-α (TNFα), localized immunohistochemically to this affected region of the pilosebaceous unit, was specifically up-regulated by ME1 in skin but not in other tissues examined. Moreover, skin inflammation was reduced by cotreatment with the TNFα signaling inhibitor, etanercept, indicating the involvement of TNFα in this inflammatory process. Interleukin-1, a cytokine that frequently acts in concert with TNFα, is also involved in this process given the efficacy of the interleukin-1 antagonist Kineret. Our results provide a mechanistic framework to develop evidence-based trials for EGFR antibody–induced skin rash in patients with cancer. [Cancer Res 2009;69(14):5643–7]Other Versions
This publication has 17 references indexed in Scilit:
- Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?Journal of Cellular Physiology, 2008
- Effect of Molecular Therapeutics on Liver Regeneration in a Murine ModelJournal of Clinical Oncology, 2008
- Mechanisms of cutaneous toxicities to EGFR inhibitorsNature Reviews Cancer, 2006
- Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitorsAnnals of Oncology, 2005
- New Advances on the Functions of Epidermal Growth Factor Receptor and Ceramides in Skin Cell Differentiation, Disorders and CancersSkin Pharmacology and Physiology, 2004
- Epidermal Growth Factor as a Biologic Switch in Hair Growth CycleOnline Journal of Public Health Informatics, 2003
- Tumor necrosis factor (TNF) receptor type 1 (p55) is a main mediator for TNF‐α‐induced skin inflammationEuropean Journal of Immunology, 1997
- The Improved Organ Maintenance of the Human Sebaceous Gland: Modeling in Vitro the Effects of Epidermal Growth Factor, Androgens, Estrogens, 13-cis Retinoic Acid, and Phenol RedJournal of Investigative Dermatology, 1996
- Tumor necrosis factorJournal of the American Academy of Dermatology, 1991
- Stimulation of Hamster Sebaceous Glands by Epidermal Growth FactorJournal of Investigative Dermatology, 1983